• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Primary Biliary Cholangitis Therapeutic Market

    ID: MRFR/HC/41680-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Primary Biliary Cholangitis Therapeutic Market Research Report By Therapeutic Class (Ursodeoxycholic Acid, Obeticholic Acid, Antihistamines, Immunosuppressants), By Route of Administration (Oral, Intravenous, Subcutaneous), By Indication (Cholestatic Liver Disease, Liver Cirrhosis, Fatigue Related Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Primary Biliary Cholangitis Therapeutic Market Research Report - Global Forecast Till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Primary Biliary Cholangitis Therapeutic Market Summary

    The Global Primary Biliary Cholangitis Therapeutic Market is projected to grow from 2.01 USD Billion in 2024 to 3.8 USD Billion by 2035.

    Key Market Trends & Highlights

    Primary Biliary Cholangitis Therapeutic Key Trends and Highlights

    • The market is expected to witness a compound annual growth rate (CAGR) of 5.96 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 3.8 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 2.01 USD Billion, reflecting the current demand for therapeutic options.
    • Growing adoption of innovative treatment options due to increasing prevalence of Primary Biliary Cholangitis is a major market driver.

    Market Size & Forecast

    2024 Market Size 2.01 (USD Billion)
    2035 Market Size 3.8 (USD Billion)
    CAGR (2025-2035) 5.96%

    Major Players

    Mylan, Alnylam Pharmaceuticals, Ferring Pharmaceuticals, Accord Healthcare, Bristol Myers Squibb, Helsinn Healthcare, InterMune, AbbVie, Zydus Cadila, Eisai, Genentech, Sanofi, Novartis, Gilead Sciences, AMAG Pharmaceuticals

    Primary Biliary Cholangitis Therapeutic Market Trends

    The Primary Biliary Cholangitis Therapeutic Market is experiencing significant growth, driven primarily by the increasing prevalence of liver diseases and the rising awareness of healthcare systems regarding chronic conditions. The development of advanced therapeutic agents has also been a strong influence on market expansion.

    Technological advances in research and treatment options have increased the number of available therapies, meeting the demand for effective management of this condition. An aging population and lifestyle changes contributing to liver-related health issues further propel the market forward, creating a heightened need for effective therapeutic solutions.Opportunities in this market can be explored by focusing on personalized medicine approaches and the development of novel drug formulations. Bio-pharmaceutical companies are increasingly investing in research to find innovative treatments targeting specific pathways involved in Primary Biliary Cholangitis.

    The introduction of combination therapies holds significant potential for improving patient outcomes. Additionally, collaborations between pharmaceutical companies and research institutions can lead to breakthroughs in treatment options, creating a more robust pipeline of therapies. The growing trend of telemedicine and digital health solutions also offers pathways for better patient management and monitoring, leading to improved quality of care.In recent times, there has been a shift toward patient-centric approaches, emphasizing the importance of patient quality of life in treatment development.

    More clinicians are focusing on holistic care, addressing not only the physical aspects of the disease but also the emotional and psychological well-being of patients. Regulatory bodies have begun to support accelerated approval processes for innovative therapies, making it easier for new treatments to reach the market. Overall, the landscape of the Primary Biliary Cholangitis Therapeutic Market is dynamic, with ongoing research, evolving treatment methodologies, and a strong focus on patient experience shaping its future trajectory.

    The evolving landscape of therapies for Primary Biliary Cholangitis suggests a growing emphasis on personalized medicine, which may enhance treatment efficacy and patient outcomes.

    U.S. National Institutes of Health

    Primary Biliary Cholangitis Therapeutic Market Drivers

    Market Growth Projections

    Increased Research Funding

    The allocation of increased funding for research into Primary Biliary Cholangitis is a crucial factor driving the Global Primary Biliary Cholangitis Therapeutic Market Industry. Government and private sector investments are being directed towards understanding the pathophysiology of PBC and developing targeted therapies. This financial support is fostering innovation and accelerating the development of new treatment options. As research progresses, the market is likely to benefit from a pipeline of novel therapies, which could enhance patient care and contribute to a projected CAGR of 5.96% from 2025 to 2035.

    Advancements in Therapeutic Options

    Innovations in treatment modalities are significantly influencing the Global Primary Biliary Cholangitis Therapeutic Market Industry. New therapies, including novel pharmacological agents and combination treatments, are emerging to enhance patient outcomes. The introduction of drugs that target specific pathways in PBC has shown promise in clinical trials, leading to improved liver function and quality of life. As these advancements continue, the market is expected to grow, with projections indicating a rise to 3.8 USD Billion by 2035. This growth underscores the importance of research and development in addressing unmet medical needs.

    Regulatory Support for New Therapies

    Regulatory bodies are increasingly supportive of the development and approval of new therapies for Primary Biliary Cholangitis, which is a key driver for the Global Primary Biliary Cholangitis Therapeutic Market Industry. Streamlined approval processes and incentives for orphan drugs are encouraging pharmaceutical companies to invest in PBC treatments. This regulatory environment fosters innovation and expedites the availability of new therapies to patients. As a result, the market is poised for growth, with expectations of reaching 3.8 USD Billion by 2035, reflecting the positive impact of regulatory frameworks on therapeutic advancements.

    Growing Awareness and Education Initiatives

    Efforts to raise awareness about Primary Biliary Cholangitis are playing a pivotal role in the Global Primary Biliary Cholangitis Therapeutic Market Industry. Educational campaigns aimed at healthcare professionals and the general public are crucial for early diagnosis and treatment. Increased awareness leads to more patients seeking medical advice, which in turn drives demand for therapeutic options. As more individuals are diagnosed and treated, the market is expected to expand significantly, with a projected value of 2.01 USD Billion in 2024, highlighting the impact of education on healthcare outcomes.

    Rising Prevalence of Primary Biliary Cholangitis

    The increasing incidence of Primary Biliary Cholangitis (PBC) is a primary driver for the Global Primary Biliary Cholangitis Therapeutic Market Industry. As awareness about autoimmune diseases grows, more cases are being diagnosed. In 2024, the market is projected to reach 2.01 USD Billion, reflecting the urgent need for effective therapies. The rise in prevalence is particularly noted among women aged 40 to 60, who are disproportionately affected. This demographic shift indicates a growing patient population that requires ongoing treatment, thereby expanding the market's potential.

    Market Segment Insights

    Primary Biliary Cholangitis Therapeutic Market Therapeutic Class Insights

    The Primary Biliary Cholangitis Therapeutic Market is witnessing substantial growth, with a market valuation reaching 2.01 USD Billion in 2024 and projected to achieve 3.8 USD Billion by 2035. This growth trajectory is supported by various therapeutic classes that are pivotal in the management of Primary Biliary Cholangitis (PBC).

    The revenue generated from the market is significantly driven by multiple treatment options, two of which stand out for their dominant market share: Ursodeoxycholic Acid and Obeticholic Acid. Ursodeoxycholic Acid holds a majority share of 0.8 USD Billion in 2024, doubling to 1.6 USD Billion by 2035, reflecting its essential role as a first-line treatment for PBC due to its ability to improve liver function and reduce fatigue.

    Obeticholic Acid, valued at 0.45 USD Billion in 2024 and expected to reach 0.9 USD Billion by 2035, also plays a significant role, acting as an alternative or adjunctive therapy for patients who are intolerant to Ursodeoxycholic Acid or do not exhibit adequate response, thereby providing critical therapeutic options.

    The segment also includes Antihistamines and Immunosuppressants, which are important yet secondary contributors in the market. Antihistamines are projected to generate a revenue of 0.3 USD Billion in 2024 and grow to 0.6 USD Billion by 2035. While they are traditionally used to manage symptoms associated with PBC, their impact on the overall treatment paradigm remains limited compared to the others.

    Similarly, Immunosuppressants, with a market value of 0.46 USD Billion in 2024 and 0.96 USD Billion in 2035, are primarily employed in more complex cases or those with autoimmune conditions concurrent with PBC. Their role, while significant, caters to a more niche patient population, indicating a lesser yet critical function in the overall therapeutic strategy for managing PBC.The growth in the Primary Biliary Cholangitis Therapeutic Market can be attributed to rising awareness about the disease and novel drug approvals providing more options for treatment.

    Primary Biliary Cholangitis Therapeutic Market Route of Administration Insights

    The Primary Biliary Cholangitis Therapeutic Market is witnessing notable growth within the Route of Administration segment, which plays a crucial role in patient adherence and treatment efficacy. The market segmentation includes various routes such as Oral, Intravenous, and Subcutaneous administration.

    Among these, the Oral route often holds a significant market share due to its convenience, leading to enhanced patient compliance.The Intravenous route is favored for rapid action, particularly in acute situations, while the Subcutaneous administration is gaining traction for its ease of use in outpatient settings.

    The growing prevalence of Primary Biliary Cholangitis (PBC) and the continuous development of advanced therapeutic solutions are driving market growth in this segment. However, challenges such as potential side effects and the complexity of administration methods may impact overall market dynamics. The Primary Biliary Cholangitis Therapeutic Market data reflects these trends, indicating opportunities for innovation in drug formulations and delivery mechanisms that could enhance patient experience and outcomes.

    Primary Biliary Cholangitis Therapeutic Market Indication Insights

    The segmentation of this market focuses on crucial indicators such as Cholestatic Liver Disease, Liver Cirrhosis, and Fatigue Related Therapy, each playing a significant role in patient management and treatment protocols. Cholestatic Liver Disease stands out due to its high prevalence among patients suffering from bile duct disorders, receiving considerable attention from healthcare providers. Liver Cirrhosis remains a key area of focus, as it impacts liver functionality and carries serious health implications, necessitating therapeutic interventions.

    Furthermore, Fatigue Related Therapy is gaining prominence as fatigue is a common and debilitating symptom in patients with Primary Biliary Cholangitis, demanding effective treatment strategies. With these critical indications, the Global Primary Biliary Cholangitis Therapeutic Market showcases a diverse array of opportunities for innovative therapies and solutions catering to the specific needs of affected patients.The overall market growth is driven by increasing awareness, advances in treatment options, and an aging population prone to liver diseases.

    Primary Biliary Cholangitis Therapeutic Market Distribution Channel Insights

    The Primary Biliary Cholangitis Therapeutic Market shows a versatile distribution channel landscape that is critical for ensuring patient access to therapeutic options. Within this market, hospital pharmacies play a pivotal role, as they directly cater to patients requiring immediate treatments in clinical settings, thus significantly contributing to overall market growth. Retail pharmacies equally serve a vital function, providing patients with convenient access to medications, fostering adherence and patient compliance, enhancing treatment outcomes for those with Primary Biliary Cholangitis.

    Online pharmacies have emerged as a significant player due to the increasing trend of e-commerce and telemedicine, offering patients the convenience of ordering prescriptions from home, which has become increasingly relevant in recent years. As the industry continues to evolve, these distribution channels are adapting to consumer needs and technological advancements, ultimately driving the Primary Biliary Cholangitis Therapeutic Market revenue higher.

    Market growth opportunities exist within these channels, as they are increasingly tailored toward enhancing patient experiences and improving treatment accessibility, aligning with the broader healthcare trends of convenience and efficiency in medication delivery systems.

    Get more detailed insights about Primary Biliary Cholangitis Therapeutic Market Research Report - Global Forecast Till 2035

    Request Free Sample

    Regional Insights

    The Primary Biliary Cholangitis Therapeutic Market exhibits significant regional dynamics, with North America leading the market, valued at 0.75 USD Billion in 2024, reflecting a robust healthcare infrastructure and increasing prevalence of liver diseases. Europe follows closely, with a valuation of 0.55 USD Billion in 2024, supported by rising awareness and advancements in healthcare services.

    The APAC region is also emerging, valued at 0.4 USD Billion in 2024, driven by an increase in patient populations and a growing focus on liver health. South America and MEA have comparatively smaller shares, valued at 0.15 USD Billion and 0.16 USD Billion in 2024, respectively, but are catching up due to increasing healthcare investments and improving access to treatments.

    The dominance of North America and Europe in the Primary Biliary Cholangitis Therapeutic Market segmentation underscores their established healthcare systems and strong research capabilities, whereas the APAC region is anticipated to experience accelerated growth due to rising healthcare access and education. Overall, understanding these regional distributions provides insight into the Primary Biliary Cholangitis Therapeutic Market revenue trends and growth drivers facilitating strategies for stakeholders.

    Primary Biliary Cholangitis Therapeutic Market Region

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Primary Biliary Cholangitis Therapeutic Market is a dynamic and evolving sector characterized by a range of treatments tailored to address the needs of patients suffering from this chronic liver disease. As the prevalence of primary biliary cholangitis continues to rise, pharmaceutical companies are engaged in extensive research and development efforts to create innovative therapies that enhance patient outcomes.

    Competitive insights in this market reveal a landscape wherein companies are not only vying for market share but also focusing on improving the quality of care through the introduction of novel treatments and patient-centric approaches. The collaboration between research institutions, healthcare providers, and pharmacological firms has become increasingly vital in pushing the boundaries of understanding and treating this condition, fostering a rich environment of competition and innovation.

    Mylan has established a noteworthy presence in the Primary Biliary Cholangitis Therapeutic Market, capitalizing on its deep expertise in drug development and its extensive portfolio of generic and branded therapeutic solutions. The company's strengths lie in its ability to leverage a global footprint for efficiency and a well-developed supply chain that allows for rapid delivery and scalability of its products. Mylan’s commitment to affordability and accessibility for patients is another significant strength, as its efforts significantly reduce barriers to entry for necessary treatments.

    Additionally, the organization focuses on strategic partnerships and collaborations that enhance its research capabilities and expand its product offerings, thereby solidifying its competitive edge in the market. Alnylam Pharmaceuticals operates with a unique focus within the Global Primary Biliary Cholangitis Therapeutic Market by prioritizing the development of RNA interference therapies, a relatively novel approach to treating this condition.

    The strengths of Alnylam Pharmaceuticals highlight its commitment to innovation and research, as the company has pioneered transformative therapies that specifically target the underlying mechanisms of primary biliary cholangitis. Its specialized knowledge in rare and genetic diseases positions Alnylam uniquely, allowing it to tap into niche segments within the market.

    Furthermore, Alnylam's strong investment in clinical trials and collaborations with leading research institutions ensures a continuous pipeline of potential drug candidates, thus enhancing its ability to adapt to emerging market needs and patient demands. This focus on cutting-edge technologies and drug mechanisms reinforces Alnylam's reputation and sustains its competitive advantage in this therapeutic landscape.

    Key Companies in the Primary Biliary Cholangitis Therapeutic Market market include

    Industry Developments

    • Q2 2024: Intercept Pharmaceuticals Announces FDA Approval of Ocaliva® (obeticholic acid) for the Treatment of Primary Biliary Cholangitis (PBC) Intercept Pharmaceuticals received FDA approval for Ocaliva® (obeticholic acid) as a treatment for primary biliary cholangitis, marking a significant regulatory milestone for the company and expanding therapeutic options for PBC patients.
    • Q1 2024: Intercept Pharmaceuticals Announces European Commission Approval of Ocaliva® for the Treatment of Primary Biliary Cholangitis The European Commission granted marketing authorization to Intercept Pharmaceuticals for Ocaliva® (obeticholic acid) for the treatment of primary biliary cholangitis, enabling commercialization across the European Union.
    • Q2 2024: GSK to Acquire Exclusive Rights to Seladelpar for Primary Biliary Cholangitis in Europe GSK announced an agreement to acquire exclusive European rights to seladelpar, a late-stage investigational therapy for primary biliary cholangitis, from CymaBay Therapeutics, strengthening its liver disease portfolio.
    • Q2 2024: CymaBay Therapeutics Announces FDA Acceptance of New Drug Application for Seladelpar in Primary Biliary Cholangitis The FDA accepted CymaBay Therapeutics' New Drug Application for seladelpar as a treatment for primary biliary cholangitis, initiating a formal review process for potential U.S. approval.
    • Q2 2024: Gilead Sciences Appoints New Head of Liver Disease Franchise Amid Expansion in PBC Research Gilead Sciences appointed a new executive to lead its liver disease franchise, signaling increased focus and investment in research and development for primary biliary cholangitis and related indications.
    • Q1 2024: Ipsen and Genfit Announce Strategic Partnership to Develop Elafibranor for Primary Biliary Cholangitis Ipsen and Genfit entered a strategic partnership to co-develop and commercialize elafibranor, an investigational therapy for primary biliary cholangitis, aiming to accelerate late-stage clinical development and regulatory submissions.
    • Q2 2024: GENFIT Announces Positive Phase 3 Results for Elafibranor in Primary Biliary Cholangitis GENFIT reported positive topline results from its Phase 3 clinical trial evaluating elafibranor in patients with primary biliary cholangitis, supporting future regulatory filings.
    • Q1 2024: Mirum Pharmaceuticals Raises $120 Million in Public Offering to Advance PBC Pipeline Mirum Pharmaceuticals completed a $120 million public offering to fund the continued development and commercialization of its pipeline therapies for primary biliary cholangitis.
    • Q2 2024: Mirum Pharmaceuticals Announces FDA Priority Review for Livmarli in Primary Biliary Cholangitis The FDA granted priority review to Mirum Pharmaceuticals' supplemental New Drug Application for Livmarli in the treatment of primary biliary cholangitis, expediting the regulatory review process.
    • Q2 2024: Calliditas Therapeutics Opens New Manufacturing Facility to Support PBC Drug Production Calliditas Therapeutics inaugurated a new manufacturing facility dedicated to the production of its investigational therapies for primary biliary cholangitis, increasing capacity for future commercial supply.
    • Q1 2025: CymaBay Therapeutics Announces FDA Approval of Seladelpar for the Treatment of Primary Biliary Cholangitis The FDA approved seladelpar, developed by CymaBay Therapeutics, for the treatment of primary biliary cholangitis, providing a new therapeutic option for patients in the United States.
    • Q2 2025: Novartis Enters Collaboration with Smaller Biotech to Develop Next-Generation PBC Therapies Novartis announced a collaboration agreement with a biotechnology company to co-develop next-generation therapies targeting primary biliary cholangitis, aiming to expand its presence in the rare liver disease market.

    Future Outlook

    Primary Biliary Cholangitis Therapeutic Market Future Outlook

    The Primary Biliary Cholangitis Therapeutic Market is projected to grow at a 5.96% CAGR from 2024 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness.

    New opportunities lie in:

    • Develop novel therapies targeting specific patient subgroups to enhance treatment efficacy.
    • Leverage digital health technologies for patient monitoring and adherence solutions.
    • Expand into emerging markets with tailored pricing strategies to increase accessibility.

    By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and increased patient access.

    Market Segmentation

    Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Primary Biliary Cholangitis Therapeutic Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Primary Biliary Cholangitis Therapeutic Market Indication Outlook

    • Cholestatic Liver Disease
    • Liver Cirrhosis
    • Fatigue Related Therapy

    Primary Biliary Cholangitis Therapeutic Market Therapeutic Class Outlook

    • Ursodeoxycholic Acid
    • Obeticholic Acid
    • Antihistamines
    • Immunosuppressants

    Primary Biliary Cholangitis Therapeutic Market Distribution Channel Outlook

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

    Primary Biliary Cholangitis Therapeutic Market Route of Administration Outlook

    • Oral
    • Intravenous
    • Subcutaneous

    Report Scope

    Attribute/Metric Source: Details
    MARKET SIZE 2023 1.89(USD Billion)
    MARKET SIZE 2024 2.01(USD Billion)
    MARKET SIZE 2035 3.8(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.98% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Mylan, Alnylam Pharmaceuticals, Ferring Pharmaceuticals, Accord Healthcare, Bristol Myers Squibb, Helsinn Healthcare, InterMune, AbbVie, Zydus Cadila, Eisai, Genentech, Sanofi, Novartis, Gilead Sciences, AMAG Pharmaceuticals
    SEGMENTS COVERED Therapeutic Class, Route of Administration, Indication, Distribution Channel, Regional
    KEY MARKET OPPORTUNITIES Increased prevalence of liver diseases, Emerging novel therapies and treatments, Growing awareness and diagnosis rates, Expansion in emerging markets, Potential for combination therapies.
    KEY MARKET DYNAMICS Increasing prevalence of cholangitis cases, Rising number of clinical trials, Advancements in drug development, Growing patient awareness and advocacy, Favorable reimbursement policies
    COUNTRIES COVERED North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the Global Primary Biliary Cholangitis Therapeutic Market in 2024?

    The Global Primary Biliary Cholangitis Therapeutic Market is expected to be valued at 2.01 billion USD in 2024.

    What is the anticipated market size for the Global Primary Biliary Cholangitis Therapeutic Market in 2035?

    By 2035, the Global Primary Biliary Cholangitis Therapeutic Market is projected to reach approximately 3.8 billion USD.

    What is the expected compound annual growth rate (CAGR) for the Global Primary Biliary Cholangitis Therapeutic Market from 2025 to 2035?

    The expected CAGR for the Global Primary Biliary Cholangitis Therapeutic Market from 2025 to 2035 is 5.98%.

    Which region is projected to have the largest share of the Global Primary Biliary Cholangitis Therapeutic Market in 2024?

    In 2024, North America is projected to have the largest share of the Global Primary Biliary Cholangitis Therapeutic Market, valued at 0.75 billion USD.

    What is the market size of the Global Primary Biliary Cholangitis Therapeutic Market in the APAC region for 2024?

    The APAC region is anticipated to have a market size of 0.4 billion USD in 2024 for the Global Primary Biliary Cholangitis Therapeutic Market.

    Which therapeutic class is expected to be the largest in the Global Primary Biliary Cholangitis Therapeutic Market by 2035?

    The Ursodeoxycholic Acid therapeutic class is expected to be the largest, with a valuation of 1.6 billion USD by 2035.

    What are the key players in the Global Primary Biliary Cholangitis Therapeutic Market?

    Key players in the Global Primary Biliary Cholangitis Therapeutic Market include Mylan, Alnylam Pharmaceuticals, Ferring Pharmaceuticals, and Bristol Myers Squibb.

    What is the expected market size for Immunosuppressants in the Global Primary Biliary Cholangitis Therapeutic Market in 2035?

    The market size for Immunosuppressants in the Global Primary Biliary Cholangitis Therapeutic Market is expected to reach 0.96 billion USD by 2035.

    What trends are driving growth in the Global Primary Biliary Cholangitis Therapeutic Market?

    Key growth drivers include advancements in therapy options and increasing awareness of primary biliary cholangitis.

    What market value is projected for the South America region in the Global Primary Biliary Cholangitis Therapeutic Market by 2035?

    The South America region is projected to reach a market value of 0.35 billion USD in the Global Primary Biliary Cholangitis Therapeutic Market by 2035.

    1. Primary Interviews and Information Gathering Process 3.4.2. Breakdown of Primary
    2. Respondents 3.5. Forecasting Model 3.6. Market Size Estimation 3.6.1. Bottom-Up
    3. Approach 3.6.2. Top-Down Approach 3.7. Data Triangulation 3.8. Validation 4. MARKET
    4. DYNAMICS 4.1. Overview 4.2. Drivers 4.3. Restraints 4.4. Opportunities 5. MARKET FACTOR ANALYSIS 5.1. Value chain Analysis 5.2. Porter's Five Forces Analysis 5.2.1.
    5. Bargaining Power of Suppliers 5.2.2. Bargaining Power of Buyers 5.2.3. Threat of
    6. New Entrants 5.2.4. Threat of Substitutes 5.2.5. Intensity of Rivalry 5.3. COVID-19
    7. Impact Analysis 5.3.1. Market Impact Analysis 5.3.2. Regional Impact 5.3.3. Opportunity
    8. and Threat Analysis 6. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET, BY THERAPEUTIC
    9. CLASS (USD BILLION) 6.1. Ursodeoxycholic Acid 6.2. Obeticholic Acid 6.3. Antihistamines
      1. Immunosuppressants 7. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET, BY ROUTE
    10. OF ADMINISTRATION (USD BILLION) 7.1. Oral 7.2. Intravenous 7.3. Subcutaneous 8.
    11. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET, BY INDICATION (USD BILLION) 8.1.
    12. Cholestatic Liver Disease 8.2. Liver Cirrhosis 8.3. Fatigue Related Therapy 9. PRIMARY
    13. BILIARY CHOLANGITIS THERAPEUTIC MARKET, BY DISTRIBUTION CHANNEL (USD BILLION) 9.1.
    14. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 10. PRIMARY BILIARY
    15. CHOLANGITIS THERAPEUTIC MARKET, BY REGIONAL (USD BILLION) 10.1. North America 10.1.1.
    16. US 10.1.2. Canada 10.2. Europe 10.2.1. Germany 10.2.2. UK 10.2.3. France 10.2.4.
    17. Russia 10.2.5. Italy 10.2.6. Spain 10.2.7. Rest of Europe 10.3. APAC 10.3.1. China
      1. India 10.3.3. Japan 10.3.4. South Korea 10.3.5. Malaysia 10.3.6. Thailand
        1. Indonesia 10.3.8. Rest of APAC 10.4. South America 10.4.1. Brazil 10.4.2.
    18. Mexico 10.4.3. Argentina 10.4.4. Rest of South America 10.5. MEA 10.5.1. GCC Countries
      1. South Africa 10.5.3. Rest of MEA 11. COMPETITIVE LANDSCAPE 11.1. Overview
      2. Competitive Analysis 11.3. Market share Analysis 11.4. Major Growth Strategy
    19. in the Primary Biliary Cholangitis Therapeutic Market 11.5. Competitive Benchmarking
      1. Leading Players in Terms of Number of Developments in the Primary Biliary
    20. Cholangitis Therapeutic Market 11.7. Key developments and growth strategies 11.7.1.
    21. New Product Launch/Service Deployment 11.7.2. Merger & Acquisitions 11.7.3.
    22. Joint Ventures 11.8. Major Players Financial Matrix 11.8.1. Sales and Operating
    23. Income 11.8.2. Major Players R&D Expenditure. 2023 12. COMPANY PROFILES 12.1.
    24. Mylan 12.1.1. Financial Overview 12.1.2. Products Offered 12.1.3. Key Developments
      1. SWOT Analysis 12.1.5. Key Strategies 12.2. Alnylam Pharmaceuticals 12.2.1.
    25. Financial Overview 12.2.2. Products Offered 12.2.3. Key Developments 12.2.4. SWOT
    26. Analysis 12.2.5. Key Strategies 12.3. Ferring Pharmaceuticals 12.3.1. Financial
    27. Overview 12.3.2. Products Offered 12.3.3. Key Developments 12.3.4. SWOT Analysis
      1. Key Strategies 12.4. Accord Healthcare 12.4.1. Financial Overview 12.4.2.
    28. Products Offered 12.4.3. Key Developments 12.4.4. SWOT Analysis 12.4.5. Key Strategies
      1. Bristol Myers Squibb 12.5.1. Financial Overview 12.5.2. Products Offered 12.5.3.
    29. Key Developments 12.5.4. SWOT Analysis 12.5.5. Key Strategies 12.6. Helsinn Healthcare
      1. Financial Overview 12.6.2. Products Offered 12.6.3. Key Developments 12.6.4.
    30. SWOT Analysis 12.6.5. Key Strategies 12.7. InterMune 12.7.1. Financial Overview
      1. Products Offered 12.7.3. Key Developments 12.7.4. SWOT Analysis 12.7.5.
    31. Key Strategies 12.8. AbbVie 12.8.1. Financial Overview 12.8.2. Products Offered
      1. Key Developments 12.8.4. SWOT Analysis 12.8.5. Key Strategies 12.9. Zydus
    32. Cadila 12.9.1. Financial Overview 12.9.2. Products Offered 12.9.3. Key Developments
      1. SWOT Analysis 12.9.5. Key Strategies 12.10. Eisai 12.10.1. Financial Overview
        1. Products Offered 12.10.3. Key Developments 12.10.4. SWOT Analysis 12.10.5.
    33. Key Strategies 12.11. Genentech 12.11.1. Financial Overview 12.11.2. Products Offered
      1. Key Developments 12.11.4. SWOT Analysis 12.11.5. Key Strategies 12.12.
    34. Sanofi 12.12.1. Financial Overview 12.12.2. Products Offered 12.12.3. Key Developments
      1. SWOT Analysis 12.12.5. Key Strategies 12.13. Novartis 12.13.1. Financial
    35. Overview 12.13.2. Products Offered 12.13.3. Key Developments 12.13.4. SWOT Analysis
      1. Key Strategies 12.14. Gilead Sciences 12.14.1. Financial Overview 12.14.2.
    36. Products Offered 12.14.3. Key Developments 12.14.4. SWOT Analysis 12.14.5. Key Strategies
      1. AMAG Pharmaceuticals 12.15.1. Financial Overview 12.15.2. Products Offered
        1. Key Developments 12.15.4. SWOT Analysis 12.15.5. Key Strategies 13. APPENDIX
      2. References 13.2. Related Reports LIST OF TABLES TABLE 1. LIST OF ASSUMPTIONS
    37. & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 3. NORTH AMERICA
    38. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    39. ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 4. NORTH AMERICA PRIMARY
    40. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION,
    41. 2035 (USD BILLIONS) TABLE 5. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    42. MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS)
    43. & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 7. US PRIMARY BILIARY
    44. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS,
    45. 2035 (USD BILLIONS) TABLE 8. US PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    46. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    47. FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 10. US PRIMARY BILIARY CHOLANGITIS
    48. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035
    49. (USD BILLIONS) TABLE 11. US PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    50. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 12. CANADA
    51. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    52. THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 13. CANADA PRIMARY BILIARY CHOLANGITIS
    53. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    54. (USD BILLIONS) TABLE 14. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    55. ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 15. CANADA
    56. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    57. DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 16. CANADA PRIMARY BILIARY
    58. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    59. (USD BILLIONS) TABLE 17. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    60. ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 18.
    61. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    62. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 19. EUROPE PRIMARY BILIARY
    63. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035
    64. (USD BILLIONS) TABLE 20. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    65. ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE
    66. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    67. BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 22. GERMANY PRIMARY BILIARY CHOLANGITIS
    68. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    69. (USD BILLIONS) TABLE 23. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    70. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    71. & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 25. GERMANY PRIMARY
    72. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION
    73. CHANNEL, 2019-2035 (USD BILLIONS) TABLE 26. GERMANY PRIMARY BILIARY CHOLANGITIS
    74. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    75. FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 28. UK PRIMARY BILIARY
    76. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    77. 2035 (USD BILLIONS) TABLE 29. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    78. SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 30.
    79. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    80. BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 31. UK PRIMARY BILIARY CHOLANGITIS
    81. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    82. FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 33. FRANCE PRIMARY
    83. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF
    84. ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 34. FRANCE PRIMARY BILIARY CHOLANGITIS
    85. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD
    86. BILLIONS) TABLE 35. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    87. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 36. FRANCE
    88. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    89. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 37. RUSSIA PRIMARY BILIARY CHOLANGITIS
    90. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    91. (USD BILLIONS) TABLE 38. RUSSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    92. ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE
    93. RUSSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    94. BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 40. RUSSIA PRIMARY BILIARY CHOLANGITIS
    95. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035
    96. (USD BILLIONS) TABLE 41. RUSSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    97. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 42. ITALY
    98. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    99. THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 43. ITALY PRIMARY BILIARY CHOLANGITIS
    100. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    101. (USD BILLIONS) TABLE 44. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    102. ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 45. ITALY
    103. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    104. DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 46. ITALY PRIMARY BILIARY CHOLANGITIS
    105. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    106. FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 48. SPAIN PRIMARY
    107. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF
    108. ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 49. SPAIN PRIMARY BILIARY CHOLANGITIS
    109. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD
    110. BILLIONS) TABLE 50. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    111. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 51. SPAIN
    112. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    113. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 52. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS
    114. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    115. (USD BILLIONS) TABLE 53. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    116. MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
    117. BILLIONS) TABLE 54. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    118. SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 55.
    119. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES &
    120. FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 56. REST OF EUROPE
    121. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    122. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 57. APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    123. MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
    124. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 59. APAC PRIMARY
    125. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION,
    126. 2035 (USD BILLIONS) TABLE 60. APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    127. MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS)
    128. FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 62. CHINA PRIMARY BILIARY
    129. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS,
    130. 2035 (USD BILLIONS) TABLE 63. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    131. MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
    132. BILLIONS) TABLE 64. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    133. & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 65. CHINA PRIMARY
    134. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION
    135. CHANNEL, 2019-2035 (USD BILLIONS) TABLE 66. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    136. MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE
    137. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    138. BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 68. INDIA PRIMARY BILIARY CHOLANGITIS
    139. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    140. (USD BILLIONS) TABLE 69. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    141. ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 70. INDIA
    142. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    143. DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 71. INDIA PRIMARY BILIARY CHOLANGITIS
    144. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    145. FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 73. JAPAN PRIMARY
    146. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF
    147. ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 74. JAPAN PRIMARY BILIARY CHOLANGITIS
    148. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD
    149. BILLIONS) TABLE 75. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    150. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 76. JAPAN
    151. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    152. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 77. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS
    153. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    154. (USD BILLIONS) TABLE 78. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    155. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    156. & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 80. SOUTH KOREA PRIMARY
    157. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION
    158. CHANNEL, 2019-2035 (USD BILLIONS) TABLE 81. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS
    159. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    160. & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 83. MALAYSIA
    161. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    162. ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 84. MALAYSIA PRIMARY BILIARY
    163. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035
    164. (USD BILLIONS) TABLE 85. MALAYSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    165. SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS)
    166. & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 87. THAILAND PRIMARY
    167. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC
    168. CLASS, 2019-2035 (USD BILLIONS) TABLE 88. THAILAND PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    169. MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
    170. BILLIONS) TABLE 89. THAILAND PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    171. ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 90. THAILAND
    172. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    173. DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 91. THAILAND PRIMARY BILIARY
    174. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    175. (USD BILLIONS) TABLE 92. INDONESIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    176. SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE
    177. INDONESIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES &
    178. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 94. INDONESIA
    179. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    180. INDICATION, 2019-2035 (USD BILLIONS) TABLE 95. INDONESIA PRIMARY BILIARY CHOLANGITIS
    181. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035
    182. (USD BILLIONS) TABLE 96. INDONESIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    183. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 97. REST
    184. OF APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    185. BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 98. REST OF APAC PRIMARY BILIARY
    186. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    187. 2035 (USD BILLIONS) TABLE 99. REST OF APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    188. MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE
    189. REST OF APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    190. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 101. REST
    191. OF APAC PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    192. BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 102. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS
    193. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    194. (USD BILLIONS) TABLE 103. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    195. MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD
    196. BILLIONS) TABLE 104. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    197. SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 105.
    198. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES &
    199. FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 106. SOUTH AMERICA
    200. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    201. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 107. BRAZIL PRIMARY BILIARY CHOLANGITIS
    202. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    203. (USD BILLIONS) TABLE 108. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    204. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    205. & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 110. BRAZIL PRIMARY
    206. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION
    207. CHANNEL, 2019-2035 (USD BILLIONS) TABLE 111. BRAZIL PRIMARY BILIARY CHOLANGITIS
    208. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    209. & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 113. MEXICO
    210. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    211. ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 114. MEXICO PRIMARY BILIARY
    212. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035
    213. (USD BILLIONS) TABLE 115. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    214. SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS)
    215. & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 117. ARGENTINA PRIMARY
    216. BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC
    217. CLASS, 2019-2035 (USD BILLIONS) TABLE 118. ARGENTINA PRIMARY BILIARY CHOLANGITIS
    218. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    219. (USD BILLIONS) TABLE 119. ARGENTINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    220. SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 120.
    221. ARGENTINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    222. BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 121. ARGENTINA PRIMARY BILIARY
    223. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    224. (USD BILLIONS) TABLE 122. REST OF SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    225. MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS)
    226. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    227. SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 125.
    228. REST OF SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    229. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 126. REST
    230. OF SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES &
    231. FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 127. MEA PRIMARY BILIARY CHOLANGITIS
    232. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    233. (USD BILLIONS) TABLE 128. MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    234. ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE
    235. MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    236. BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 130. MEA PRIMARY BILIARY CHOLANGITIS
    237. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035
    238. (USD BILLIONS) TABLE 131. MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE
    239. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 132. GCC COUNTRIES
    240. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    241. THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE 133. GCC COUNTRIES PRIMARY BILIARY
    242. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    243. 2035 (USD BILLIONS) TABLE 134. GCC COUNTRIES PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    244. MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE
    245. GCC COUNTRIES PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES
    246. & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 136. GCC
    247. COUNTRIES PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    248. BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 137. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS
    249. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035
    250. (USD BILLIONS) TABLE 138. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    251. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    252. & FORECAST, BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 140. SOUTH AFRICA
    253. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY
    254. DISTRIBUTION CHANNEL, 2019-2035 (USD BILLIONS) TABLE 141. SOUTH AFRICA PRIMARY BILIARY
    255. CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    256. (USD BILLIONS) TABLE 142. REST OF MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    257. SIZE ESTIMATES & FORECAST, BY THERAPEUTIC CLASS, 2019-2035 (USD BILLIONS) TABLE
    258. REST OF MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES &
    259. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 144. REST OF
    260. MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST,
    261. BY INDICATION, 2019-2035 (USD BILLIONS) TABLE 145. REST OF MEA PRIMARY BILIARY CHOLANGITIS
    262. THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035
    263. (USD BILLIONS) TABLE 146. REST OF MEA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    264. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 147.
    265. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL TABLE 148. ACQUISITION/PARTNERSHIP LIST
    266. OF FIGURES FIGURE 1. MARKET SYNOPSIS FIGURE 2. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS
    267. THERAPEUTIC MARKET ANALYSIS FIGURE 3. US PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    268. MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 4. US PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    269. MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 5. US PRIMARY BILIARY CHOLANGITIS
    270. THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 6. US PRIMARY BILIARY CHOLANGITIS
    271. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 7. US PRIMARY BILIARY
    272. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 8. CANADA PRIMARY BILIARY
    273. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 9. CANADA PRIMARY
    274. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE
    275. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION
    276. CHANNEL FIGURE 12. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    277. BY REGIONAL FIGURE 13. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    278. CLASS FIGURE 15. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    279. BY ROUTE OF ADMINISTRATION FIGURE 16. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    280. MARKET ANALYSIS BY INDICATION FIGURE 17. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    281. MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 18. GERMANY PRIMARY BILIARY CHOLANGITIS
    282. THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 19. UK PRIMARY BILIARY CHOLANGITIS
    283. THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 20. UK PRIMARY BILIARY CHOLANGITIS
    284. THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 21. UK PRIMARY BILIARY
    285. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 22. UK PRIMARY BILIARY
    286. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 23. UK PRIMARY
    287. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 24. FRANCE PRIMARY
    288. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 25.
    289. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    290. CHANNEL FIGURE 28. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    291. BY REGIONAL FIGURE 29. RUSSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    292. BY THERAPEUTIC CLASS FIGURE 30. RUSSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    293. ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 31. RUSSIA PRIMARY BILIARY CHOLANGITIS
    294. THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 32. RUSSIA PRIMARY BILIARY CHOLANGITIS
    295. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 33. RUSSIA PRIMARY BILIARY
    296. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 34. ITALY PRIMARY BILIARY
    297. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 35. ITALY PRIMARY
    298. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE
    299. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION
    300. CHANNEL FIGURE 38. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    301. BY REGIONAL FIGURE 39. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    302. BY THERAPEUTIC CLASS FIGURE 40. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    303. ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 41. SPAIN PRIMARY BILIARY CHOLANGITIS
    304. THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 42. SPAIN PRIMARY BILIARY CHOLANGITIS
    305. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 43. SPAIN PRIMARY BILIARY
    306. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 44. REST OF EUROPE PRIMARY
    307. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 45.
    308. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE
    309. OF ADMINISTRATION FIGURE 46. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    310. MARKET ANALYSIS BY INDICATION FIGURE 47. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS
    311. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 48. REST OF EUROPE PRIMARY
    312. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 49. APAC PRIMARY
    313. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS FIGURE 50. CHINA PRIMARY BILIARY
    314. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 51. CHINA PRIMARY
    315. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE
    316. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION
    317. CHANNEL FIGURE 54. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    318. BY REGIONAL FIGURE 55. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    319. BY THERAPEUTIC CLASS FIGURE 56. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    320. ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 57. INDIA PRIMARY BILIARY CHOLANGITIS
    321. THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 58. INDIA PRIMARY BILIARY CHOLANGITIS
    322. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 59. INDIA PRIMARY BILIARY
    323. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL FIGURE 60. JAPAN PRIMARY BILIARY
    324. CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY THERAPEUTIC CLASS FIGURE 61. JAPAN PRIMARY
    325. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE
    326. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION
    327. CHANNEL FIGURE 64. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    328. BY REGIONAL FIGURE 65. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET
    329. ANALYSIS BY THERAPEUTIC CLASS FIGURE 66. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS
    330. THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 67. SOUTH KOREA PRIMARY
    331. BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 68. SOUTH KOREA
    332. PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    333. REGIONAL FIGURE 70. MALAYSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC MARKET ANALYSIS
    334. BY THERAPEUTIC CLASS FIGURE 71. MALAYSIA PRIMARY BILIARY CHOLANGITIS THERAPEUTIC
    335. MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 72. MALAYSIA PRIMARY BILIARY CHOLANGITIS
    336. THERAPEUTIC MARKET ANALYSIS BY INDICATION FIGURE 73. MALAYSIA PRIMARY BILIARY CHOLANGITIS
    337. THERAPEUTIC MARKET ANALYSIS BY DISTRIBUTION CHANNEL FIGURE 74. MALAYSIA PRIMARY
    338. BILIARY CHOLANGITIS THER

    Primary Biliary Cholangitis Therapeutic Market Segmentation

    • Primary Biliary Cholangitis Therapeutic Market By Therapeutic Class (USD Billion, 2019-2035)

      • Ursodeoxycholic Acid
      • Obeticholic Acid
      • Antihistamines
      • Immunosuppressants

     

    • Primary Biliary Cholangitis Therapeutic Market By Route of Administration (USD Billion, 2019-2035)

      • Oral
      • Intravenous
      • Subcutaneous

     

    • Primary Biliary Cholangitis Therapeutic Market By Indication (USD Billion, 2019-2035)

      • Cholestatic Liver Disease
      • Liver Cirrhosis
      • Fatigue Related Therapy

     

    • Primary Biliary Cholangitis Therapeutic Market By Distribution Channel (USD Billion, 2019-2035)

      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Pharmacy

     

    • Primary Biliary Cholangitis Therapeutic Market By Regional (USD Billion, 2019-2035)

      • North America
      • Europe
      • South America
      • Asia Pacific
      • Middle East and Africa

     

    Primary Biliary Cholangitis Therapeutic Market Regional Outlook (USD Billion, 2019-2035)

     

     

    • North America Outlook (USD Billion, 2019-2035)

      • North America Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • North America Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • North America Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • North America Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

      • North America Primary Biliary Cholangitis Therapeutic Market by Regional Type

        • US
        • Canada
      • US Outlook (USD Billion, 2019-2035)

      • US Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • US Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • US Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • US Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • CANADA Outlook (USD Billion, 2019-2035)

      • CANADA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • CANADA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • CANADA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • CANADA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

    • Europe Outlook (USD Billion, 2019-2035)

      • Europe Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • Europe Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • Europe Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • Europe Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

      • Europe Primary Biliary Cholangitis Therapeutic Market by Regional Type

        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Spain
        • Rest of Europe
      • GERMANY Outlook (USD Billion, 2019-2035)

      • GERMANY Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • GERMANY Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • GERMANY Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • GERMANY Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • UK Outlook (USD Billion, 2019-2035)

      • UK Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • UK Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • UK Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • UK Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • FRANCE Outlook (USD Billion, 2019-2035)

      • FRANCE Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • FRANCE Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • FRANCE Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • FRANCE Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • RUSSIA Outlook (USD Billion, 2019-2035)

      • RUSSIA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • RUSSIA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • RUSSIA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • RUSSIA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • ITALY Outlook (USD Billion, 2019-2035)

      • ITALY Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • ITALY Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • ITALY Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • ITALY Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • SPAIN Outlook (USD Billion, 2019-2035)

      • SPAIN Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • SPAIN Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • SPAIN Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • SPAIN Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • REST OF EUROPE Outlook (USD Billion, 2019-2035)

      • REST OF EUROPE Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • REST OF EUROPE Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • REST OF EUROPE Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • REST OF EUROPE Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

    • APAC Outlook (USD Billion, 2019-2035)

      • APAC Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • APAC Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • APAC Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • APAC Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

      • APAC Primary Biliary Cholangitis Therapeutic Market by Regional Type

        • China
        • India
        • Japan
        • South Korea
        • Malaysia
        • Thailand
        • Indonesia
        • Rest of APAC
      • CHINA Outlook (USD Billion, 2019-2035)

      • CHINA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • CHINA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • CHINA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • CHINA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • INDIA Outlook (USD Billion, 2019-2035)

      • INDIA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • INDIA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • INDIA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • INDIA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • JAPAN Outlook (USD Billion, 2019-2035)

      • JAPAN Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • JAPAN Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • JAPAN Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • JAPAN Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • SOUTH KOREA Outlook (USD Billion, 2019-2035)

      • SOUTH KOREA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • SOUTH KOREA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • SOUTH KOREA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • SOUTH KOREA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • MALAYSIA Outlook (USD Billion, 2019-2035)

      • MALAYSIA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • MALAYSIA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • MALAYSIA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • MALAYSIA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • THAILAND Outlook (USD Billion, 2019-2035)

      • THAILAND Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • THAILAND Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • THAILAND Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • THAILAND Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • INDONESIA Outlook (USD Billion, 2019-2035)

      • INDONESIA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • INDONESIA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • INDONESIA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • INDONESIA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • REST OF APAC Outlook (USD Billion, 2019-2035)

      • REST OF APAC Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • REST OF APAC Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • REST OF APAC Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • REST OF APAC Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

    • South America Outlook (USD Billion, 2019-2035)

      • South America Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • South America Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • South America Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • South America Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

      • South America Primary Biliary Cholangitis Therapeutic Market by Regional Type

        • Brazil
        • Mexico
        • Argentina
        • Rest of South America
      • BRAZIL Outlook (USD Billion, 2019-2035)

      • BRAZIL Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • BRAZIL Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • BRAZIL Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • BRAZIL Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • MEXICO Outlook (USD Billion, 2019-2035)

      • MEXICO Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • MEXICO Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • MEXICO Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • MEXICO Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • ARGENTINA Outlook (USD Billion, 2019-2035)

      • ARGENTINA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • ARGENTINA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • ARGENTINA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • ARGENTINA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

      • REST OF SOUTH AMERICA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • REST OF SOUTH AMERICA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • REST OF SOUTH AMERICA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • REST OF SOUTH AMERICA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

    • MEA Outlook (USD Billion, 2019-2035)

      • MEA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • MEA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • MEA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • MEA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy

      • MEA Primary Biliary Cholangitis Therapeutic Market by Regional Type

        • GCC Countries
        • South Africa
        • Rest of MEA
      • GCC COUNTRIES Outlook (USD Billion, 2019-2035)

      • GCC COUNTRIES Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • GCC COUNTRIES Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • GCC COUNTRIES Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • GCC COUNTRIES Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • SOUTH AFRICA Outlook (USD Billion, 2019-2035)

      • SOUTH AFRICA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • SOUTH AFRICA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • SOUTH AFRICA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • SOUTH AFRICA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • REST OF MEA Outlook (USD Billion, 2019-2035)

      • REST OF MEA Primary Biliary Cholangitis Therapeutic Market by Therapeutic Class Type

        • Ursodeoxycholic Acid
        • Obeticholic Acid
        • Antihistamines
        • Immunosuppressants

      • REST OF MEA Primary Biliary Cholangitis Therapeutic Market by Route of Administration Type

        • Oral
        • Intravenous
        • Subcutaneous

      • REST OF MEA Primary Biliary Cholangitis Therapeutic Market by Indication Type

        • Cholestatic Liver Disease
        • Liver Cirrhosis
        • Fatigue Related Therapy

      • REST OF MEA Primary Biliary Cholangitis Therapeutic Market by Distribution Channel Type

        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027